All News about Bluebird BioVia Benzinga
(BLUE) - Analyzing bluebird bio's Short Interest
February 29, 2024
Via Benzinga
Is CRISPR Therapeutics the NVIDIA of gene editing?
February 26, 2024
Via MarketBeat
Topics
Artificial Intelligence
Gene Therapy For Beta-Thalassemia: CRISPR Therapeutics/Vertex's Casgevy Secures FDA Nod Ahead of Schedule
January 17, 2024
Via Benzinga
Exposures
Product Safety
2 Red Flags for Bluebird Bio Stock
January 10, 2024
Via The Motley Fool
From bluebird bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
December 21, 2023
Via Benzinga
S&P 500 Edges Lower; General Mills Cuts Sales Forecast
December 20, 2023
Via Benzinga
Topics
Stocks
Exposures
US Equities
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|